Numerous drugs across multiple drug classes are available for the treatment of MDD. Yet current therapies are not sufficiently effective in all patients, and those patients with TRD have…
Most patients with chronic obstructive pulmonary disease (COPD) in the five European countries under study receive treatment shortly after diagnosis. The progressive nature of the disease results…
The diabetic nephropathy (DN) market is poised to expand rapidly over the next decade as late-stage therapies reach the G7 markets. These agents represent the first potential disease-modifying…
NSCLC has one of the most dynamic drug development pipelines in oncology, including multiple targeted and biomarker-driven therapies. DRG expects the NSCLC therapy market to experience robust…
Hyperkalemia, a condition of elevated serum potassium, arises from disturbances to potassium homeostasis within the body. Among key populations, including patients with kidney disorders and/or HF,…
Progress in R&D and technology, regulatory and monetary incentives for advancing the development of treatments for rare diseases, and ongoing focus by the pharmaceutical market on this space are…
The Parkinson’s disease (PD) market is in the midst of transformation: the first new levodopa formulation (Rytary) in over a decade has launched with more on the horizon (e.g., ND-0612, AP-CD/…
Acute heart failure (AHF) is one of the leading causes of hospitalization in the United States, representing a significant healthcare burden. AHF patients experience high rates of mortality and…
Renal anemia is a common complication of chronic kidney disease (CKD). Although treatment options exist for renal anemia, physicians, patients, and healthcare systems are concerned over some…
In recent years therapeutic options for ovarian cancer have increased. Prior to 2016, the only targeted therapy approved for the indication was AstraZeneca’s Lynparza. However, the treatment…
The wet age-related macular degeneration (AMD) market in the United States is unique given that the key approved therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea, and Novartis’s…
Although several effective anti-inflammatory agents and bronchodilators are available to control disease in mild-to-moderate asthmatics, great unmet need exists in the treatment of severe disease…
The type 2 diabetes market has become increasingly crowded, with therapies competing over preferential formulary placement as well as patient share. Using primary research from U.S…
A patient with major depressive disorder (MDD) who does not achieve adequate response to more than two different trials of antidepressant drugs is then usually considered as having treatment-…
Biomarker-targeted therapies are distinguished from other oncology drugs in that they are accompanied by a diagnostic test that can identify a specific patient type most likely to benefit from…
